A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Diabetic Retinopathy Clinical Trial

Official title:

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05038020
• Other study ID #: AKST4290-231
• Status: Terminated
• Phase: Phase 2
• Start date: August 17, 2021
• Est. completion date: April 19, 2022

Study information

• Verified date: October 2023
• Source: Alkahest, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).

Description:

This study is designed to evaluate the efficacy of AKST4290 administered at a total daily dose (TDD) of 800 mg daily (400 mg twice daily [b.i.d.]) compared with placebo over a 24-week dosing period in participants with moderately severe non-proliferative diabetic retinopathy (NPDR) to severe NPDR. Participants will be enrolled and allocated to 1 of 2 treatment arms in a 2:1 randomization scheme (AKST4290: placebo). Participants will receive treatment for a total of 24 weeks with either AKST4290 800 mg daily (400 mg b.i.d.) in Arm 1 or placebo (matching tablets) in Arm 2

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: April 19, 2022
• Est. primary completion date: December 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Type 1 or type 2 DM.

3. BCVA ETDRS visual acuity letter score= 69 letters at Screening.

4. Moderately severe NPDR (DRSS Level 47) to severe NPDR (DRSS Level 53).

Exclusion Criteria:

1. Evidence of neovascularization (NV) (including active iris or angle NV) requiring treatment, per investigator discretion.

2. PRP or grid laser within 1000 microns of the foveal center.

3. Center-InvolvedI-Diabetic Macular Edema (CI-DME) on clinical examination (CI is defined as DME within 1,000 microns of the foveal center).

4. Prior Intraocular of periocular steroid Injection

5. Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to enrollment and assignment to a randomized treatment.

6. History of vitreoretinal surgery.

7. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization.

8. History of DME or DR treatment with laser or intraocular injections of medication.

9. Medical history or condition that, in the opinion of the investigator would preclude participation in the study.

10. Clinically relevant abnormal laboratory value at Screening, including hematology, blood chemistry, or urinalysis (laboratory testing may be repeated once during the Screening phase).

11. Malignancy for which the participant has undergone resection, radiation, or chemotherapy within the past 5 years (treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed).

12. Concurrent participation in another interventional clinical trial; prior clinical trial participants must have been off study agents for at least 30 days for small molecules, 4 months for disease modifying therapies, and 1 year for vaccine or immunotherapy trials prior to Screening.

Related Conditions & MeSH terms

• Diabetic Retinopathy
• Retinal Diseases

Intervention

Drug:
• AKST4290
Oral AKST4290
• Placebo
Oral Placebo

Locations

Country	Name	City	State
United States	Site 122	Arlington	Texas
United States	Site 133	Beaufort	South Carolina
United States	Site 130	Bellaire	Texas
United States	Site 116	Clearwater	Florida
United States	Site 123	Glendale	California
United States	Site 126	Harlingen	Texas
United States	Site 134	Houston	Texas
United States	Site 121	Huntington Beach	California
United States	Site 129	Katy	Texas
United States	Site 127	Ladson	South Carolina
United States	Site 120	Oak Forest	Illinois
United States	Site 132	Phoenix	Arizona
United States	Site 136	Phoenix	Arizona
United States	Site 125	Salt Lake City	Utah
United States	Site 128	San Antonio	Texas
United States	Site 117	Sarasota	Florida
United States	Site 118	Winter Haven	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Alkahest, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Investigate the Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline.	The Diabetic Retinopathy Severity Scale (DRSS) divides DR into 13 levels ranging from the absence of retinopathy to severe retinopathy and is used to describe overall DR severity as well as the change in severity over time. Higher scores indicate more severe DR.; To be eligible for the study, participants needed to have moderately severe non-proliferative DR (NPDR) (DRSS Level 47) to severe NPDR (DRSS Level 53) in one eye, and at least mild NPDR (DRSS Level 35) to mild proliferative DR (PDR) (DRSS Level 61) in the other eye at baseline.; The DRSS score is derived from fundus photography (FP) and fluorescein angiography (FA) findings.; The primary efficacy endpoint is the proportion of participants with a = 3-step improvement from baseline on the DRSS score as compared with Week 24.	Baseline to Week 24
Secondary	To Investigate Additional Measures of Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline.	The Diabetic Retinopathy Severity Scale (DRSS) divides DR into 13 levels ranging from the absence of retinopathy to severe retinopathy and is used to describe overall DR severity as well as the change in severity over time. Higher scores indicate more severe DR.; The DRSS score is derived from fundus photography (FP) and fluorescein angiography (FA) findings.; The secondary efficacy endpoint is the proportion of participants with a = 2-step improvement from baseline on the DRSS score as compared with Week 24.	Baseline to Week 24 or 28
Secondary	To Assess the Proportion of Participants Progressing to (or Worsening of) Center-involved Diabetic Macular Edema (CI-DME), Proliferative Diabetic Retinopathy (PDR), and/or Anterior-segment Neovascularization (ASNV).	The secondary efficacy endpoint is the proportion of participants progressing to the following vision-threatening complications that require treatment: CI-DME, PDR, and/or ASNV as assessed by spectral domain optical coherence tomography (SD-OCT), fundus photography (FP), and fluorescein angiography (FA), as appropriate. The central reading center must confirm progression to CI-DME and PDR before treatment is initiated; progression to ASNV, and subsequent treatment, does not require photo documentation.	Baseline to Week 28
Secondary	To Assess the Time to Event of CI-DME, PDR, and/or ASNV Requiring Treatment.	The secondary efficacy endpoint is the time to the following vision-threatening event(s) that require treatment: CI-DME, PDR, and/or ASNV	Baseline to Week 28
Secondary	To Assess the Overall Safety of AKST429	Safety was assessed based on the number of participants who reported adverse events of mild, moderate or severe intensities.	Baseline to Week 28
Secondary	To Assess the Effect of AKST4290 on Diabetic Kidney Disease	The secondary efficacy endpoint is the effect of AKST4290 on diabetic kidney disease as assessed by changes in clinical laboratory values over time (eg, estimated glomerular filtration rate [eGFR], urine albumin to creatinine ratio [UACR]).	Baseline to Week 28
Secondary	To Evaluate the Changes From Baseline in the Workplace Productivity and Activity Impairment General Health (WPAI-GH) Questionnaire.	The WPAI-GH V2.0 is a 6-question survey used to assess the effects of a participant's health problems (i.e., physical or emotional problems or symptoms) on their ability to work and perform regular activities during the past seven days. The WPAI-GH questions will be analyzed as impairment percentages, in which higher percentages indicate greater impairment and less productivity.; The following parameters will be calculated (multiply scores by 100 to express in percentages): Percent of work time missed due to health: Q2 divided by (Q2 plus Q4); Percent of impairment while working due to health: Q5 divided by 10; Percent of overall work impairment due to health: Q2 divided by (Q2 plus Q4) plus [(1 - (Q2 divided by (Q2 plus Q4 ))) multiplied by (Q5 divided by 10)]; Percent of activity impairment due to health: Q6 divided by 10	Baseline to Week 24